Tivantinib

Tivantinib

File:Tivantinib structure.svg
Systematic (IUPAC) name
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione
Clinical data
Legal status	Investigational
Routes of administration	Oral
Identifiers
CAS Number	905854-02-6
ATC code	none
PubChem	CID: 11494412
ChemSpider	9669218
ChEMBL	CHEMBL2103882
Synonyms	ARQ197; ARQ-197
Chemical data
Formula	C23H19N3O2
Molecular mass	369.42 g/mol
SMILES C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
InChI InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2, (H,25,27,28)/t19-,20-/m0/s1 Key:UCEQXRCJXIVODC-PMACEKPBSA-N

Tivantinib (ARQ197; by Arqule, Inc.) is an experimental anti-cancer drug. It is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro. Tivantinib is being tested clinically as a highly selective MET inhibitor. However, the mechanism of action of tivantinib is still unclear.

Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET.

Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer.